A Phase II, Multicenter, Single-Arm Study of MPDL2380A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This multicenter, single- arm study will evaluate the efficacy and safety of MPD L3280A in
patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer.
Patients will receive MPDL3280A 1200 mg intravenously every 3 weeks for a maximum of 16
cycles (or 12 months, whichever occurs first) in the a bsence of unacceptable toxicity or
symptomatic deterioration attributed to disea se progression. Patients who complete the
initial treatment stage may be eligibl e fro MPDL3280A re-treatment upon subsequent disease
progression during the foll ow-up period without intervening systemic anti-cancer therapy.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.